MiNK Therapeutics (INKT) Earnings Date & Reports

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

INKT is expected to report earnings to rise 52.63% to -87 cents per share on August 12

MiNK Therapeutics INKT Stock Earnings Reports

Q2'26

Est.

$-0.87

Q1'26

Missed

by $0.39

Q4'25

Missed

by $0.44

Q3'25

Missed

by $0.58

Q2'25

Missed

by $0.99

The last earnings report on May 15 showed earnings per share of -56 cents, missing the estimate of -18 cents. With 8.30K shares outstanding, the current market capitalization sits at 60.81M.

View a ticker or compare two or three

Compare

INKT

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for INKT